Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes.
In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.
“Poor glycemic control (A1C above 9.0%) places patients at high risk for long-term complications and negatively impacts health care costs. Exploring new treatment options which translate into improved glycemic control can benefit patients and have positive implications for health care costs and utilization,” lead author Dr. Patricia Wu said in prepared remarks.
